Cargando…
Escherichia coli recombinant expression of SARS-CoV-2 protein fragments
We have developed a method for the inexpensive, high-level expression of antigenic protein fragments of SARS-CoV-2 proteins in Escherichia coli. Our approach uses the thermophilic family 9 carbohydrate-binding module (CBM9) as an N-terminal carrier protein and affinity tag. The CBM9 module was joine...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817660/ https://www.ncbi.nlm.nih.gov/pubmed/35123472 http://dx.doi.org/10.1186/s12934-022-01753-0 |
_version_ | 1784645694592647168 |
---|---|
author | McGuire, Bailey E. Mela, Julia E. Thompson, Vanessa C. Cucksey, Logan R. Stevens, Claire E. McWhinnie, Ralph L. Winkler, Dirk F. H. Pelech, Steven Nano, Francis E. |
author_facet | McGuire, Bailey E. Mela, Julia E. Thompson, Vanessa C. Cucksey, Logan R. Stevens, Claire E. McWhinnie, Ralph L. Winkler, Dirk F. H. Pelech, Steven Nano, Francis E. |
author_sort | McGuire, Bailey E. |
collection | PubMed |
description | We have developed a method for the inexpensive, high-level expression of antigenic protein fragments of SARS-CoV-2 proteins in Escherichia coli. Our approach uses the thermophilic family 9 carbohydrate-binding module (CBM9) as an N-terminal carrier protein and affinity tag. The CBM9 module was joined to SARS-CoV-2 protein fragments via a flexible proline–threonine linker, which proved to be resistant to E. coli proteases. Two CBM9-spike protein fragment fusion proteins and one CBM9-nucleocapsid fragment fusion protein largely resisted protease degradation, while most of the CBM9 fusion proteins were degraded at some site in the SARS-CoV-2 protein fragment. All of the fusion proteins were highly expressed in E. coli and the CBM9-ID-H1 fusion protein was shown to yield 122 mg/L of purified product. Three purified CBM9-SARS-CoV-2 fusion proteins were tested and found to bind antibodies directed to the appropriate SARS-CoV-2 antigenic regions. The largest intact CBM9 fusion protein, CBM9-ID-H1, incorporates spike protein amino acids 540–588, which is a conserved region overlapping and C-terminal to the receptor binding domain that is widely recognized by human convalescent sera and contains a putative protective epitope. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01753-0. |
format | Online Article Text |
id | pubmed-8817660 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-88176602022-02-07 Escherichia coli recombinant expression of SARS-CoV-2 protein fragments McGuire, Bailey E. Mela, Julia E. Thompson, Vanessa C. Cucksey, Logan R. Stevens, Claire E. McWhinnie, Ralph L. Winkler, Dirk F. H. Pelech, Steven Nano, Francis E. Microb Cell Fact Research We have developed a method for the inexpensive, high-level expression of antigenic protein fragments of SARS-CoV-2 proteins in Escherichia coli. Our approach uses the thermophilic family 9 carbohydrate-binding module (CBM9) as an N-terminal carrier protein and affinity tag. The CBM9 module was joined to SARS-CoV-2 protein fragments via a flexible proline–threonine linker, which proved to be resistant to E. coli proteases. Two CBM9-spike protein fragment fusion proteins and one CBM9-nucleocapsid fragment fusion protein largely resisted protease degradation, while most of the CBM9 fusion proteins were degraded at some site in the SARS-CoV-2 protein fragment. All of the fusion proteins were highly expressed in E. coli and the CBM9-ID-H1 fusion protein was shown to yield 122 mg/L of purified product. Three purified CBM9-SARS-CoV-2 fusion proteins were tested and found to bind antibodies directed to the appropriate SARS-CoV-2 antigenic regions. The largest intact CBM9 fusion protein, CBM9-ID-H1, incorporates spike protein amino acids 540–588, which is a conserved region overlapping and C-terminal to the receptor binding domain that is widely recognized by human convalescent sera and contains a putative protective epitope. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12934-022-01753-0. BioMed Central 2022-02-05 /pmc/articles/PMC8817660/ /pubmed/35123472 http://dx.doi.org/10.1186/s12934-022-01753-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data. |
spellingShingle | Research McGuire, Bailey E. Mela, Julia E. Thompson, Vanessa C. Cucksey, Logan R. Stevens, Claire E. McWhinnie, Ralph L. Winkler, Dirk F. H. Pelech, Steven Nano, Francis E. Escherichia coli recombinant expression of SARS-CoV-2 protein fragments |
title | Escherichia coli recombinant expression of SARS-CoV-2 protein fragments |
title_full | Escherichia coli recombinant expression of SARS-CoV-2 protein fragments |
title_fullStr | Escherichia coli recombinant expression of SARS-CoV-2 protein fragments |
title_full_unstemmed | Escherichia coli recombinant expression of SARS-CoV-2 protein fragments |
title_short | Escherichia coli recombinant expression of SARS-CoV-2 protein fragments |
title_sort | escherichia coli recombinant expression of sars-cov-2 protein fragments |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8817660/ https://www.ncbi.nlm.nih.gov/pubmed/35123472 http://dx.doi.org/10.1186/s12934-022-01753-0 |
work_keys_str_mv | AT mcguirebaileye escherichiacolirecombinantexpressionofsarscov2proteinfragments AT melajuliae escherichiacolirecombinantexpressionofsarscov2proteinfragments AT thompsonvanessac escherichiacolirecombinantexpressionofsarscov2proteinfragments AT cuckseyloganr escherichiacolirecombinantexpressionofsarscov2proteinfragments AT stevensclairee escherichiacolirecombinantexpressionofsarscov2proteinfragments AT mcwhinnieralphl escherichiacolirecombinantexpressionofsarscov2proteinfragments AT winklerdirkfh escherichiacolirecombinantexpressionofsarscov2proteinfragments AT pelechsteven escherichiacolirecombinantexpressionofsarscov2proteinfragments AT nanofrancise escherichiacolirecombinantexpressionofsarscov2proteinfragments |